EHS
EHS

Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration




doi: 10.1111/jvp.13082.


Online ahead of print.

Affiliations

Item in Clipboard

Alissa B Mones et al.


J Vet Pharmacol Ther.


.

Abstract

Maropitant citrate is a synthetic neurokinin-1 receptor antagonist and substance P inhibitor used for control of emesis in dogs in cats. Maropitant citrate is used empirically in birds, despite a lack of pharmacokinetic data in avian species. The objective of this study was to determine the pharmacokinetic profile of a single dose of maropitant citrate 1 and 2 mg/kg subcutaneously (SC) in eight Rhode Island Red hens (Gallus gallus domesticus). A crossover study design was used with 1-week washout between trials. Blood samples were collected over 36 h after drug administration. Plasma concentrations were measured using liquid chromatography-tandem mass spectrometry and pharmacokinetic parameters were determined via non-compartmental analysis. The mean maximum plasma concentration, time to maximum concentration, and elimination half-life following 1 and 2 mg/kg SC were 915.6 ± 312.8 ng/ml and 1195.2 ± 320.2 ng/ml, 0.49 ± 0.21 h and 1.6 ± 2.6 h, and 8.47 ± 2.24 h and 8.58 ± 2.6 h, respectively. Pharmacokinetic data suggests doses of 1 or 2 mg/kg SC may be administered every 12-24 h to maintain above target plasma concentration similar to dogs (90 ng/ml). These data provide a basis for further investigation of maropitant citrate pharmacokinetics and pharmacodynamics in birds.


Keywords:

antiemetic; avian; maropitant; neurokinin-1 agonist; substance P.

References

REFERENCES

    1. Bello, A., Poźniak, B., Smutkiewicz, A., & Świtała, M. (2022). The influence of the site of drug administration on florfenicol pharmacokinetics in turkeys. Poult Sci J, 101(1), 101536.

    1. Benchaoui, H. A., Cox, S. R., Schneider, R. P., Boucher, J. F., & Clemence, R. G. (2007). The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol, 30(4), 336-344.

    1. Boscan, P., Monnet, E., Mama, K., Twedt, D. C., Congdon, J., & Steffey, E. P. (2011). Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation of the ovary in dogs. Am J Vet Res, 72(12), 1576-1579.

    1. De la Puente-Redondo, V. A., Siedek, E. M., Benchaoui, H. A., Tilt, N., Rowan, T. G., & Clemence, R. G. (2007). The anti-emetic efficacy of maropitant (Cerenia™) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. J Small Anim Pract, 48(2), 93-98.

    1. Diemunsch, P., & Grélot, L. (2000). Potential of substance P antagonists as antiemetics. Drugs, 60, 533-546.



Source link

EHS
Back to top button